Study on Vismodegib for Patients with Advanced or Metastatic Basal Cell Carcinoma

Inclusion Criteria

• For patients with metastatic BCC, confirmation that the cancer has spread to distant parts of the body.
• For patients with locally advanced BCC, at least one tumor that is 10 mm or larger and confirmation from a surgeon that it cannot be removed or surgery is not suitable.
• Patients with locally advanced BCC should have received radiation therapy unless it is not appropriate. If radiation was given, the disease must have worsened afterward.
• Patients with Gorlin syndrome can join if they meet the criteria for advanced or metastatic disease.
• Patients with measurable or non-measurable disease are eligible.
• Must have adequate organ function.
• Women who can become pregnant must agree to use two forms of birth control, including one barrier method, during the study and for 12 months after stopping Vismodegib.
• Men with female partners who can become pregnant must agree to use a latex condom and advise their partner to use another form of birth control during the study and for 3 months after stopping Vismodegib.

Exclusion Criteria

• Pregnant or breastfeeding women.
• Life expectancy of less than 12 weeks.
• Receiving other cancer treatments not specified in the study.
• Must have completed any recent cancer treatment at least 21 days before starting the study.
• Uncontrolled medical conditions, such as infections needing IV antibiotics.
• Any other health issues that could interfere with the study or increase the risk of complications.
• Unwilling to use effective birth control methods.